## Lytgobi (futibatinib) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:		MEMBER'S FIRST NAME:	
	g., chart notes or lab data, to su		additional documentation that is equest). Information contained in
MATARED INCORMATION			URGENT
MEMBER INFORMATION		ELDOT MANAGE	
LAST NAME:		FIRST NAME:	
PHONE NUMBER:		DATE OF BIRTH:	
STREET ADDRESS:			
CITY:		STATE: ZIP CODE:	
PATIENT INSURANCE ID NU	JMBER:		
FOLLOWING LINK: PRIMETHERAPEUTICS.CC  PATIENT'S AUTHORIZED REI	CRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLED IN THE PHI DISCLED IN T	:	
PRESCRIBER INFORMATIO	N		
LAST NAME:		FIRST NAME:	
PRESCRIBER SPECIALTY:		EMAIL ADDRESS:	
NPI NUMBER:		DEA NUMBER:	
PHONE NUMBER:		FAX NUMBER:	
STREET ADDRESS:		1	
CITY:		STATE: ZIP C	ODE:
REQUESTOR (if different than prescriber):		OFFICE CONTACT PERSON:	
		1	
MEDICATION OR MEDICA	L DISPENSING INFORMATION		
MEDICATION NAME:			
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:
NEW THERAPY DURATION OF THERAPY (SI	RENEWAL	IF RENEWAL: DATE THE	RAPY INITIATED:
DONATION OF THERAPT (3)	LCITIC DATESJ.		

Continued on next page.



## Lytgobi (futibatinib) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST	NAME:
1. HAS THE PATIENT TRIED ANY OTHE	R MEDICATIONS FOR THIS CONDITION?	YES (if yes, complete below) NO
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	<b>DURATION OF THERAPY</b> (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:
2. LIST DIAGNOSES:		ICD-10:
☐ Intrahepatic cholangiocarcinoma		
□ Other diagnosis:ICD·	-10	
<b>3. REQUIRED CLINICAL INFORMATION</b> PRIOR AUTHORIZATION.	: PLEASE PROVIDE ALL RELEVANT CLINIC	CAL INFORMATION TO SUPPORT A
Yes □ No Please provide documentati	logist?   Yes   No  ectable, locally advanced or metastatic i	
Does patient have the fibroblast grow No Please provide documentation.	rth factor receptor 2 (FGFR2) gene fusio	ns or other rearrangements?   Yes
Has patient been previously treated we chemotherapy? ☐ Yes ☐ No Please pro	vith at least one prior systemic gemcital ovide documentation.	bine and platinum-based
Has patient had prior treatment with Truseltiq(infigratinib)?   Yes   No Ple	another FGFR inhibitor such as Pemazy ease provide documentation.	re(pemigatinib) or
Renewal Requests:  Does patient continue to demonstrate	e a positive clinical response?   Yes   N	No Please provide documentation.
Are there any other comments, diagnophysician feels is important to this rev		ailed, and/or any other information the
*Please note: Not all drugs/diagnoses information is received.	are covered on all plans. This request m	ay be denied unless all required



## Lytgobi (futibatinib) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:			
<b>ATTESTATION:</b> I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.				
Prescriber Signature or Electronic I.D. Verification:	Date:			
you are not the intended recipient, you are hereby notified that any d	nission contain confidential health information that is legally privileged. If lisclosure, copying, distribution, or action taken in reliance on the contents ormation in error, please notify the sender immediately (via return FAX)			

**FAX THIS FORM TO: 800-424-7640** 

MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program Attn: CP-4201

P.O. Box 64811 St. Paul, MN 55164-0811 Phone: 877-228-7909

